Search hospitals
>
New Hampshire
>
Lebanon
Dartmouth-Hitchcock Medical Center
Claim this profile
Lebanon, New Hampshire 03766
Global Leader in Lung Cancer
Global Leader in Cancer
Conducts research for Breast Cancer
Conducts research for Pancreatic Cancer
Conducts research for Non-Small Cell Lung Cancer
1082 reported clinical trials
83 medical researchers
Summary
Dartmouth-Hitchcock Medical Center is a medical facility located in Lebanon, New Hampshire. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer and other specialties. Dartmouth-Hitchcock Medical Center is involved with conducting 1,082 clinical trials across 1,270 conditions. There are 83 research doctors associated with this hospital, such as Julie Kim, Kathryn C. Hourdequin, Konstantin H. Dragnev, and Manik A. Amin.
Area of expertise
Lung Cancer
Dartmouth-Hitchcock Medical Center has run 91 trials for Lung Cancer. Some of their research focus areas include:
Cancer
Dartmouth-Hitchcock Medical Center has run 84 trials for Cancer. Some of their research focus areas include:
Top PIs
Julie Kim
Dartmouth Hitchcock Medical Center
8 years of reported clinical research
Kathryn C. Hourdequin
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
9 years of reported clinical research
Konstantin H. Dragnev
Dartmouth Hitchcock Medical Center
6 years of reported clinical research
Manik A. Amin
Washington University School of Medicine
7 years of reported clinical research
Clinical Trials running at Dartmouth-Hitchcock Medical Center
Lung Cancer
Cancer
Multiple Myeloma
Breast Cancer
Brain Tumor
Non-Small Cell Lung Cancer
Ovarian Cancer
Heart Attack
Pancreatic Cancer
Abdominal Aortic Aneurysm
Dato-DXd + Pembrolizumab
for Advanced Lung Cancer
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non-squamous histology.
Recruiting
2 awards
Phase 3
13 criteria
Daraxonrasib
for Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Recruiting
2 awards
Phase 3
4 criteria
Zongertinib
for Lung Cancer
This study is open to adults 18 years and older who have early-stage non-small cell lung cancer (NSCLC). Their cancer must have a specific change in a gene called HER2. Genes provide the instructions for making proteins, and this change leads to a faulty HER2 protein. People can join if their lung cancer was removed by surgery, and they have already received certain other anti-cancer treatments. The purpose of this study is to find out if a study medicine called zongertinib helps people with this type of cancer live longer without their cancer coming back after surgery, when compared to standard treatment. Zongertinib is being developed to target the faulty HER2 protein, which can cause cancer cells to grow. In this study, participants are assigned by chance to one of two treatment groups, with an equal chance of being in either group. One group takes the study medicine, zongertinib, by mouth once a day for up to 3 years. The other group receives a standard treatment, chosen by their doctor. This standard treatment may be an immunotherapy medicine given by infusion into a vein every 3 or 4 weeks for up to 1 year, or regular check-ups without active study medicine (observation). Participants can be in this study for up to about 11 years. During this time, they visit the study site regularly for check-ups and study-related tests. The frequency of these visits varies depending on their treatment and how long they have been in the study. In addition to visits at the study site, participants in some treatment groups will also have phone calls with the study team every 3 weeks to check on their health between their scheduled visits. Doctors check for any signs of cancer coming back using imaging scans (like CT or MRI scans); these scans are generally done every 3 months for the first 2 years, then every 6 months for the next 3 years, and then yearly. Participants also fill in questionnaires about their overall wellbeing, health and symptoms. Throughout the study, doctors also check participants' health and note any unwanted effects.
Recruiting
2 awards
Phase 3
6 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Dartmouth-Hitchcock Medical Center?
Dartmouth-Hitchcock Medical Center is a medical facility located in Lebanon, New Hampshire. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer and other specialties. Dartmouth-Hitchcock Medical Center is involved with conducting 1,082 clinical trials across 1,270 conditions. There are 83 research doctors associated with this hospital, such as Julie Kim, Kathryn C. Hourdequin, Konstantin H. Dragnev, and Manik A. Amin.
Where is Dartmouth-Hitchcock Medical Center located?
**Directions to Dartmouth-Hitchcock Medical Center, Lebanon, NH:** - From I-89, take Exit 18 and follow Route 120 for about 3 miles. Look for the Dartmouth-Hitchcock Medical Center sign. - For real-time driving directions, consider using Waze.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Dartmouth-Hitchcock Medical Center, contact the Dartmouth Health Billing Customer Service team at 844-808-0730. They can assist with billing, payments, insurance plans, and financial assistance policies. Financial assistance applications are available in person at Dartmouth Health locations, over the phone, or via download from the Dartmouth Health website.
What insurance does Dartmouth-Hitchcock Medical Center accept?
Dartmouth-Hitchcock Medical Center accepts the following medical insurance plans: - ElevateHealth HSA Plan - ElevateHealth HRA Plan - Choice Health Plan The ElevateHealth Plans are in partnership with Dartmouth Hitchcock Medical Center and Clinics, Elliot Health System, and Harvard Pilgrim Health Care. The Choice Health Plan provides a national network of providers, covering both in-network and out-of-network providers with varying deductibles and coinsurance.
What awards or recognition has Dartmouth-Hitchcock Medical Center received?
Dartmouth-Hitchcock Medical Center (DHMC) ranks as the highest-scoring hospital in New Hampshire according to Newsweek's America's Best-In-State Hospitals 2024 list. DHMC is also certified as a Comprehensive Stroke Center by The Joint Commission, showcasing its expertise in managing complex stroke cases.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.